• New Basement Membrane Extract Discovery Lifts Uncertainty For Clinical Trials

    Bio-IT World | But do different BME brands affect drug responses and gene expressions in organoids? To determine the answer, researchers at the Salk Institute tested out different BMEs to see their effects on pancreatic cancer organoids.

    Mar 21, 2024
  • 2024 Innovative Practices Winners in Informatics, Collaboration, Clinical IT, Genomics

    Bio-IT World | Bio-IT World today announced the 2024 Innovative Practices Awards winners. Six projects were honored. Companies driving the winning entries included AstraZeneca, DNAnexus, Pistoia Alliance, Regeneron, Tempus, and UK Biobank.

    Mar 19, 2024
  • Five Global Teams Tackling Cancer Grand Challenges

    Bio-IT World | Cancer Grand Challenges—a global funding initiative co-founded by the National Cancer Institute and Cancer Research UK—has announced five new global teams selected to each receive up to $25M over five years to take on four of cancer’s toughest challenges.

    Mar 14, 2024
  • Citizen-Driven Research Aids Development Of Digital Biomarkers For ALS

    Bio-IT World | When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less.

    Mar 13, 2024
  • Biology-Based Diagnostic Criteria For Parkinson’s Disease Research

    Bio-IT World | Scientists from a trio of countries are calling for a new, more comprehensive way of classifying Parkinson’s disease for diagnostic research purposes that considers an individual’s biology. The disorder might thereby be detected before patients have any symptoms, as is now the case for cancer and diabetes.

    Mar 12, 2024
  • Human Biomolecular Atlas Program Update

    Bio-IT World | The NIH Common Fund Human Biomolecular Atlas Program (HuBMAP) is trying to map—to create a reference atlas—of the 37 trillion human cells in our body. Work is underway on a male and female reference atlas that could help us better understand what is normal when we are healthy and help shed light on how we change as we age or as other bodily changes, such as pregnancy, occur.

    Mar 7, 2024
  • Adama Ibrahim on Embracing Change and Overcoming Resistance

    Bio-IT World | Change naturally happens everywhere. Yet, it is often met with resistance—sometimes even with outright hostility. But in an ever-evolving world, change is needed to inspire innovation and create new opportunities, and the biotech industry is no different. The question is, how do we overcome resistance?

    Mar 6, 2024
  • Bio-IT World Launches Exclusive Venture, Investing Event

    Bio-IT World | The Bio-IT World Conference & Expo has launched a new co-located event this year—the Bio-IT World Venture, Innovation, and Partnering Conference, held on Wednesday, April 17, overlapping with the last day of the Bio-IT World Conference.

    Mar 5, 2024
  • Oxford Nanopore and Lonza Team Up, Medidata and Sanofi Vaccines Collaborate, More

    Bio-IT World | Oxford Nanopore and Lonza have teamed up to cGMP validate and commercialize a first-of-its-kind novel test to accurately determine multiple critical quality attributes of mRNA products by directly sequencing both the DNA template and the messenger RNA; Parse updates whole transcriptome kit; and more.

    Feb 29, 2024
  • Ginkgo Bioworks Announces Three Acquisitions

    Bio-IT World | Ginkgo Bioworks announced three acquisitions today: Reverie Labs, Proof Diagnostics, and Patch Biosciences. The acquisitions will expand Ginkgo’s capabilities for large-scale AI foundation models, its library of RNA programmable, non-Cas enzymes, and its machine learning models and downstream assays.

    Feb 28, 2024
  • Follow the Money: Cancer Early Detection Tests, Self-Sampling Solutions Expansion, Multiple Product Advancement

    Bio-IT World | Freenome will advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platform; Capitainer plans to advance its journey toward becoming the foremost provider of self-sampling solutions with new funding, including scaling up production capacity, enhancing sales and marketing strategies, and launching new products; COUR will advance multiple, wholly owned product candidates that leverage the company’s immune tolerance platform, including Phase 2a proof-of-concept clinical studies in Myasthenia Gravis and Type 1 Diabetes, and other pipeline opportunities; and more.

    Feb 28, 2024
  • Ultima’s Silicon Wafer Sequencing Launches on $100 Genome, Part Per Million Accuracy

    Bio-IT World | Among the sequencing news at AGBT earlier this month, Ultima Genomics announced the commercial launch of its UG 100 ultra-high throughput sequencing platform.

    Feb 27, 2024
  • Why It Is Vital to Help IT and Scientists Collaborate

    Bio-IT World | In the race to unlock the power of artificial intelligence (AI) for business, it is tempting to focus on the need to strategically leverage data—indeed, this is a message that I reinforce constantly when onboarding new clients. But there’s a step that must happen first.

    Feb 23, 2024
  • Proteomics Approach Working Its Way To The Clinic For Stubborn Cancers

    Bio-IT World | For roughly half of patients with recurrence of often-deadly glioblastoma multiforme (GBM), their tumors are characterized by cells that look a lot like healthy neurons. The mimicry trick was discovered by proteomics, which has opened a view to tumor alterations unavailable through genetics alone.

    Feb 22, 2024
  • Latest Oral Insulin Drug Making Its Way To Clinical Trials

    Bio-IT World | More than a century has passed since the discovery of insulin, the world's first life-saving treatment for diabetes, and it is still being delivered via injection despite several brushes with success in developing an oral version of the drug. Hope is again on the horizon with the emergence of an oral nanotherapeutic formulation of insulin that comes with the possibility of reducing if not eliminating hypoglycemic events.

    Feb 20, 2024
  • New Vaccinology Rulebook Needed To Outsmart ‘Part-Time Pathogens’

    Bio-IT World | Researchers at University of California San Diego School of Medicine have found that the rules of vaccinology need to be reversed for Staphylococcus aureus (SA), the common and sometimes dangerous bacteria that humans encounter shortly after birth and are continuously exposed to for the remainder of their life.

    Feb 15, 2024
  • Study Establishes ENPP1 As A Biomarker For Immunotherapy Benefit

    Bio-IT World | Researchers in California have shown that breast cancer patients with RNA expression levels of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) in the bottom 50th percentile can confidently be treated with Keytruda (pembrolizumab) as well as surgery. Their cancer would have a zero percent chance of metastasizing in seven years.

    Feb 14, 2024
  • Novel NGS-Based Assay Has Seemingly Limitless Virus Detection Potential

    Bio-IT World | Scientists at the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health have created a next-generation sequencing (NGS) technology that employs oligonucleotides (oligos)—short single strands of synthetic DNA—as bait for relevant targets of detection.

    Feb 13, 2024
  • GenAI’s Real Potential in Biopharma: As a Cross-Function R&D Assistant

    Bio-IT World | In biopharma R&D there is growing momentum around the use of Generative AI, the deep-learning algorithms capable of distilling complex knowledge into easily digestible summaries. But so far companies have been relatively modest in their ambitions for the technology.

    Feb 9, 2024
  • New Patient Scoring Method To Enable Precision Medicine For Chronic Diseases

    Bio-IT World | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.

    Feb 7, 2024